Open access · CC-BY
via OpenAlex
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
Kazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, Sadatsugu Sakane, Olivier Govaere, Simon Cockell, Daisuke Motooka, Naruyasu Kakita, Yukinori Yamada, Yasuteru Kondo, Yuki Tahata, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Yoshihiro Kamada
Hepatology · 2021 · ▲ 178 citations
Abstract
BACKGROUND AND AIMS: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. APPROACH AND RESULTS: Global RNA sequencing of liver tissue from 98 patients with biopsy-proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished NASH from nonalcoholic fatty liver (NAFL), and patients with NASH exhibited molecular abnormalities reflecting their pathological features. Transcriptomic analysis identified proteins up-regulated in NASH and/or advanced fibrosis (stage F3-F4), including matricellular glycoprotein thrombospondin-2 (TSP-2), encoded by the thrombospondin 2 (THBS2) gene. The intrahepatic THBS2 expression level showed the highest areas under the receiver operating characteristic curves (AUROCs) of 0.915 and 0.957 for diagnosing NASH and advanced fibrosis, respectively. THBS2 positively correlated with inflammation and ballooning according to NAFLD activity score, serum aspartate aminotransferase and hyaluronic acid (HA) levels, and NAFLD Fibrosis Score (NFS). THBS2 was associated with extracellular matrix and collagen biosynthesis, platelet activation, caspase-mediated cleavage of cytoskeletal proteins, and immune cell infiltration. Serum TSP-2 expression was measured in 213 patients with biopsy-proven NAFLD, was significantly higher in NASH than in NAFL, and increased parallel to fibrosis stage. The AUROCs for predicting NASH and advanced fibrosis were 0.776 and 0.856, respectively, which were comparable to Fibrosis-4 index, serum HA level, and NFS in advanced fibrosis diagnosis. Serum TSP-2 level and platelet count were independent predictors of NASH and advanced fibrosis. Serum TSP-2 levels could stratify patients with NAFLD according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events. CONCLUSIONS: TSP-2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/hep.31995
- Canonical
- link ↗
- Fetched
- 2026-07-25 MST
Cite this
APA
Kozumi, K., Kodama, T., Murai, H., Sakane, S., Govaere, O., Cockell, S., Motooka, D., Kakita, N., Yamada, Y., Kondo, Y., Tahata, Y., Yamada, R., Hikita, H., Sakamori, R., Kamada, Y., Daly, A.K., Anstee, Q.M., Tatsumi, T., Morii, E., & Takehara, T. (2021). Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis. <em>Hepatology</em>. https://doi.org/10.1002/hep.31995
Vancouver
Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. 2021. doi:10.1002/hep.31995.
BibTeX
@article{kazuhiro2021Transc,
title = {Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis},
author = {Kazuhiro Kozumi and Takahiro Kodama and Hiroki Murai and Sadatsugu Sakane and Olivier Govaere and Simon Cockell and Daisuke Motooka and Naruyasu Kakita and Yukinori Yamada and Yasuteru Kondo and Yuki Tahata and Ryoko Yamada and Hayato Hikita and Ryotaro Sakamori and Yoshihiro Kamada and Ann K. Daly and Quentin M. Anstee and Tomohide Tatsumi and Eiichi Morii and Tetsuo Takehara},
journal = {Hepatology},
year = {2021},
doi = {10.1002/hep.31995},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Diabetes & Metabolism 2021
Open access · OA
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
In Vitro Cellular & Developmental Biology - Animal 2023
Open access · CC-BY
Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells
Frontiers in Pharmacology 2025
Open access · CC-BY
Targeting natural antioxidant polyphenols to protect neuroinflammation and neurodegenerative diseases: a comprehensive review
Frontiers in Neurology 2020
Open access · CC-BY
Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
npj Parkinson s Disease 2025
Open access · CC-BY
Multiomics approach identifies dysregulated lipidomic and proteomic networks in Parkinson’s disease patients mutated in TMEM175
Journal of Hepatology 2016
Citation only